Objectives: To evaluate the clinical outcomes and relapse rates in neurosarcoidosis patients administered infliximab.
Methods: A systematic review was conducted using the MEDLINE, EMBASE, SCOPUS, and Cochrane Library databases. The search included studies from their inception to March 2023.